Purpose: The purpose of this study was to characterize the population-based pharmacokinetic (POP-PK) profile of imipenem in Vietnamese adult patients and to assess the probability of target attainment (PTA) of the pharmacokinetic/pharmacodynamic (PK/PD) parameter to determine the optimal dose. Patients and Methods: A POP-PK model of imipenem was developed in patients with severe infection from a 1500-bed general hospital in Vietnam, using MONOLIX 2019. After the initial dose infusion, 6 blood samples per patient were collected to measure plasma imipenem levels. Eight covariates (eg, age, weight) were investigated to ascertain their influence on imipenem’s PK. Monte Carlo simulations were performed to determine the PTA for the time in which the total steady-state imipenem concentrations remained above the MIC (T>MIC) for 40% and 100% of the dosing interval. Results: The best fit to the PK data was a two-compartment model with inter-individual variability (IIV) in clearance (CL), central volume of distribution (Vc), intercompartmental clearance (Q), and peripheral volume of distribution (Vp). Only creatinine clearance was retained as a covariate on CL in the final model. The typical value of CL and Vc were estimated to be 4.79 L/h and 11.1 L, respectively. The between-subject variability in this population was noted to be high (> 38%, especially for IIV on Q at 110%). Prolonged or continuous infusion demonstrated efficacy (40% T>MIC) against bacteria with a MIC of 4mg/L. To achieve 100% T>MIC or bacteria with MIC> 4 mg/L, however, the number of doses must be increased while maintaining the same daily dose for the 3-hour prolonged infusion regimen. Conclusion: A population pharmacokinetic model of imipenem was developed for Vietnamese adult patients with severe illness. By using Monte Carlo simulation, the appropriate dose has been suggested based on the bacterial MIC value and the targeted PK/PD goal.
Background/Objective: Traditional therapeutic drug monitoring is limited by manual interpretation and specific constraints like sampling at steady-state and requiring a minimum of two drug concentrations. The integration of model-informed precision dosing (MIPD) into population health informatics represents a promising approach to address drug safety and efficacy. This article explored the integration of MIPD within population health informatics and evaluated its potential to enhance precision dosing using artificial intelligence (AI), machine learning (ML), and electronic health records (EHRs). Methods: PubMed and Embase searches were conducted, and all relevant peer-reviewed studies in English published between 1958 and December 2024 were included if they pertained to MIPD and population-level health, with the use of AI/ML algorithms to predict individualized drug dosing requirements. Emphasis was placed on vulnerable populations such as critically-ill, geriatric, and pediatric groups. Results: MIPD with the Bayesian method represents a scalable innovation in precision medicine, with significant implications for population health informatics. By combining AI/ML with comprehensive electronic health records (EHRs), MIPD can offer real-time, precise dosing adjustments. This integration has the potential to improve patient safety, optimize therapeutic outcomes, and reduce healthcare costs, especially for vulnerable populations where evidence is limited. Successful implementation requires collaboration among clinicians, pharmacists, and health informatics professionals, alongside secure data management and interoperability solutions. Conclusions: Further research is needed to define, implement, and evaluate practical applications of AI/ML. This insight may help develop standards and identify drugs for MIPD to advance personalized medicine within population health informatics.
Background: Bayesian area under the curve (AUC)–guided vancomycin dosing, preferably with 2 samples (2S), is recommended for pediatric patients. However, the timing of sampling may not always be convenient in the clinical setting. In low- to middle-income countries, the implementation of model-informed precision dosing (MIPD) using the Bayesian approach remains limited because of high software costs. Using MIPD with Bayesian analysis, the authors compared the accuracy and precision of midpoint and guideline-recommended 2S strategies and evaluated the clinical utility of an open-source software package and compared it with PrecisePK. Methods: This retrospective cohort study was conducted at 2 pediatric hospitals with a combined 2000 beds from April 2022 to April 2023. The authors enrolled patients aged from 3 months to 16 years who received at least 2 doses of vancomycin and had at least 2 measured drug concentrations: Cmax (1–2 hours after the end of infusion), Cmid (midpoint of the dosing interval), and Ctrough (30 minutes–1 hour before the next dose). The accuracy and precision of pharmacokinetic parameters were calculated using and , respectively. Results: Eighty children with 226 vancomycin concentrations were included. The median age was 1.6 (interquartile range 0.88–3.01) years, the average weight was 10.0 (8.0–12.0) kg, the baseline serum creatinine concentration was 0.43 (0.38–0.53) mg/dL, and the empirical vancomycin dose was 60 (57–61) mg/kg/d. Most subjects received empirical vancomycin for pneumonia (75%) and bacteremia (26%), and 75% were admitted to the intensive care unit. Compared with the 2S monitoring state, the accuracy and precision of the midpoint for the Bayesian-derived AUC24 values were 5.02% and 6.45%, respectively. Compared with PrecisePK, the AUC24 estimation by Shiny exhibited an accuracy and precision of −5.58% and 6.09%, respectively. Conclusions: Midpoint concentration offers a convenient sampling approach to accurately monitor vancomycin therapy in hospitalized pediatric patients. Shiny serves as an alternative Bayesian MIPD tool for dosing and monitoring vancomycin therapy in children in Vietnam.
4 October 2024 in International Journal of Clinical Pharmacy
Purpose: CYP3A5 polymorphisms have been associated with variations in the pharmacokinetics of tacrolimus (Tac) in kidney transplant patients. Our study aims to quantify how the CYP3A5 genotype influences tacrolimus trough concentrations (C0) in a Vietnamese outpatient population by selecting an appropriate population pharmacokinetic model of Tac for our patients. Patients and Methods: The external dataset was obtained prospectively from 54 data of adult kidney transplant recipients treated at the 103 Military Hospital. All published Tac population pharmacokinetic models were systematically screened from PubMed and Scopus databases and were selected based on our patient’s available characteristics. Mean absolute prediction error (MAPE), mean prediction error, and goodness-of-fit plots were used to identify the appropriate model for finding the formula that identifies the influence of CYP3A5 genotype on the pharmacokinetic data of Vietnamese patients. Results: The model of Zhu et al had a good predictive ability with MAPE of 19.29%. The influence of CYP3A5 genotype on tacrolimus clearance was expressed by the following formulas: <![CDATA[${\rm{CL/F = 27,2 \times }}\left[{\left({{\rm{WT/70}}} \right){\rm{0,75}}} \right]{\rm{ \times }}\left[{\left({{\rm{HCT/0,35}}} \right){\rm{ - 0,501}}} \right]\rm{\rm{ \times }}\left[{\left({{\rm{POD/180}}} \right){\rm{0,0306}}} \right]{\rm{ \times CYP3A5 }}\left({{\rm{L/h}}} \right)$]]>. The simulation result showed that Tac C0 was significantly higher in patients not expressing CYP3A5 (p< 0.001). Conclusion: The incorporation of the CYP3A5 phenotype into Zhu’s structural model has significantly enhanced our ability to predict Tacrolimus trough levels in the Vietnamese population. This study’s results underscore the valuable role of CYP3A5 phenotype in optimizing the forecast of Tac concentrations, offering a promising avenue to assist health-care practitioners in their clinical decision-making and ultimately advance patient care outcomes.
28 March 2025 in VietNam Military Medical Unisversity
Mục tiêu: Phân tích tình hình sử dụng vancomycin trong điều trị nhiễm khuẩn trên người bệnh (NB) trưởng thành tại Bệnh viện Đa khoa Hà Đông. Phương pháp nghiên cứu: Nghiên cứu hồi cứu, mô tả cắt ngang trên 129 bệnh án của NB nội trú, có sử dụng vancomycin tiêm truyền tĩnh mạch từ 01/6/2022 - 31/5/2023 tại Bệnh viện Đa khoa Hà Đông. Kết quả: Quần thể NB trong nghiên cứu có độ tuổi trung bình là 62 ± 15 tuổi, nam giới chiếm đa số (70,5%). NB ra viện với tình trạng khỏi/đỡ chiếm 78,3%. Tỷ lệ NB được chỉ định nuôi cấy vi sinh là 100%, với 52 mẫu bệnh phẩm cho kết quả dương tính, chủ yếu là vi khuẩn Staphylococcus aureus (44,2%). Vancomycin được chỉ định theo kinh nghiệm ở 63,6% NB. 22,5% NB được kê đơn liều nạp. Liều duy trì phổ biến: 1g/12 giờ (52,3%) và 0,5g/12 giờ (32,0%). Kết luận: Chỉ 22,5% NB được kê đơn liều nạp vancomycin, với 27,6% trong số đó dùng liều thấp hơn khuyến cáo. Liều duy trì phổ biến nhất là 1g/12 giờ và 0,5g/12 giờ, nhưng được sử dụng trên NB có chức năng thận khác nhau. Do đó, bệnh viện cần đẩy mạnh hoạt động dược lâm sàng nhằm tối ưu hóa chế độ liều dùng vancomycin tại bệnh viện.